Back

Edoxaban for stroke prevention in routine practice patients with atrial fibrillation with and without atherosclerotic disease: a post-hoc sub-study of ETNA-AF-Europe

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Novel anticoagulants and indications Anticoagulants ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Tim Anthonie Christiaan de Vries

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

7 More presentations in this session

Presentation thumbnail
Factor XI activity in ST-segment elevation myocardial infarction
Doctor M. Spagnolo (Catania, IT)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants or warfarin in patients with left ventricular thrombus: a meta-analysis of randomized clinical trials
Doctor M. Maqsood (Houston, US)
Abstract Slides Video
Presentation thumbnail
Direct Oral Anticoagulants versus Vitamin K Antagonists for the management of left ventricular thrombus after myocardial infarction: A meta-analysis
Doctor C. Gogos (Thessaloniki, GR)
Abstract Slides Video
Presentation thumbnail
Unfractionated heparin or low molecular weight heparin in patients with acute pulmonary embolism: a meta-analysis of randomized controlled trials
Doctor M. Maqsood (Houston, US)
Abstract Slides Video
Presentation thumbnail
Antithrombotic strategies after cryptogenic stroke: a systematic review, pairwise, and network meta-analysis of randomized controlled trials
Doctor M. Abouzid (Poznan, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Novel anticoagulants and indications

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Low rates of haemorrhagic stroke, not increased by age, renal/hepatic impairment, concomitant anti-platelet use and high CHA2DS2-VASc scores, in the 4-year follow-up of ETNA-AF-Europe
thumbnail
Congress Presentation
Incidence, management and outcomes of patients with incident atrial fibrillation in the contemporary direct oral anti coagulants era. A national study
thumbnail
Congress Presentation
Impact of different dose reduction criteria on dose assignment of current DOACs and related outcomes: an analysis from 4-year data of the ETNA-AF Europe programme

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources